Overview

This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at our institution will be enrolled.

The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype.

Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis ) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.

Eligibility

Inclusion Criteria:

• patients with cardiac amyloidosis, defined according to the recommendation provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data at our institution and with at least one follow-up visit.

Exclusion Criteria:

• missing data
• decline to the study participation